Context Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$39.7M | -$29.9M | -$25.1M | -$15.4M | -$10.5M |
| Cash from operations | -$26.4M | -$14.6M | -$21.0M | -$13.5M | -$8.8M |
| Capital expenditure | $33,948 | $7,316 | $0 | $36,836 | $0 |
| Free cash flow | -$26.4M | -$14.6M | -$21.0M | -$13.6M | -$8.8M |
| Total assets | $68.5M | $98.1M | $16.1M | $38.0M | $51.3M |
| Total liabilities | $8.0M | $2.9M | $4.2M | $3.2M | $3.0M |
Shares outstanding 91.9M · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.